The Pharma Data

DECEMBER 12, 2020

. “The tireless work to develop a new vaccine to prevent this novel, serious and life-threatening disease in an expedited timeframe after its emergence is a true testament to scientific innovation and public-private collaboration worldwide.” Centers for Disease Control and Prevention advisory panel.

Vaccine 52

Vaccine FDA Approval FDA Nurses 52

The Pharma Data

DECEMBER 11, 2020

Health care workers and nursing home residents and staff should get the first shots, according to guidelines issued recently by the U.S. Centers for Disease Control and Prevention. “This disease progresses very quickly and can get very ugly very fast. Doctors say this reflects India’s younger and leaner population.

Vaccine 52

Vaccine FDA Hospitals Doctors 52

The Pharma Data

MAY 15, 2021

The product is made here, in the USA, in our FDA approved and GMP certified facility, under sterile, strict and precise standards. For questions or concerns about any medical conditions you may have, please contact your doctor. Products are not intended to diagnose, treat, cure or prevent any disease.

Production 52

Production Packaging Nurses FDA Approval 52

PLOS: DNA Science

JUNE 1, 2023

The newest FDA-approved gene therapy treats the severe, skin-peeling condition dystrophic epidermolysis bullosa (DEB). The gene treatment has been a long time coming, but it differs from the handful of other approved gene therapies: it isn’t a one-and-done. Earlier results were published in Nature Medicine.

FDA Approval 52

FDA Approval Therapies FDA Disease 52

The Pharma Data

MAY 16, 2021

Every capsule is made here, in the USA, in our FDA approved and GMP certified facility, under sterile, strict and precise standards. For questions or concerns about any medical conditions you may have, please contact your doctor. Products are not intended to diagnose, treat, cure or prevent any disease.

Production 52

Production Nurses FDA Approval Packaging 52

The Pharma Data

JUNE 18, 2021

Undetectable minimal residual disease (uMRD) was achieved in 77% of patients in peripheral blood and 60% of patients in bone marrow. 2,3 CLL is predominately a disease of the elderly, with a median age at diagnosis of 70 years and is more common among men than women. IMBRUVICA is the only FDA-approved medicine in WM and cGVHD.

Treatment 40

Treatment FDA FDA Approval Therapies 40

The Pharma Data

JUNE 18, 2021

The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent review committee (IRC) with a HR 0.216 (95% CI, 0.131-0.357; p < 0.0001), demonstrating a reduction in the risk of disease progression or death for I+V of approximately 78% compared to C+O. . About the GLOW Study.

Treatment 52

Treatment Therapies FDA FDA Approval 52